l e t t e r s
Mobilization of hematopoietic stem and progenitor cells (HSPCs) from bone marrow into peripheral blood by the cytokine granulocyte colony-stimulating factor (G-CSF) has become the preferred source of HSPCs for stem cell transplants [1] [2] [3] [4] [5] [6] [7] [8] [9] . However, G-CSF fails to mobilize sufficient numbers of stem cells in up to 10% of donors, precluding autologous transplantation in those donors or substantially delaying transplant recovery time 2 . Consequently, new regimens are needed to increase the number of stem cells in peripheral blood upon mobilization. Using a forward genetic approach in mice, we mapped the gene encoding the epidermal growth factor receptor (Egfr) to a genetic region modifying G-CSF-mediated HSPC mobilization. Amounts of EGFR in HSPCs inversely correlated with the cells' ability to be mobilized by G-CSF, implying a negative role for EGFR signaling in mobilization. In combination with G-CSF treatment, genetic reduction of EGFR activity in HSPCs (in waved-2 mutant mice) or treatment with the EGFR inhibitor erlotinib increased mobilization. Increased mobilization due to suppression of EGFR activity correlated with reduced activity of cell division control protein-42 (Cdc42), and genetic Cdc42 deficiency in vivo also enhanced G-CSF-induced mobilization. Our findings reveal a previously unknown signaling pathway regulating stem cell mobilization and provide a new pharmacological approach for improving HSPC mobilization and thereby transplantation outcomes.
Cytokine-induced mobilization of HSPCs is evolutionarily conserved from mice to humans, such that inbred strains of mice are considered a valuable experimental system for studies that can be translated to humans. Much of the current knowledge about the cellular and molecular events regulating G-CSF-induced mobilization comes from studying this process in mice. Using a forward genetic approach and a congenic mouse model, we previously identified linkage between a locus on mouse chromosome 11 and regulation of HSPC mobilization 10 . In a congenic line named B6.D2 chr11 (line G) derived from genetic crosses between C57BL/6 and DBA/2 mice, a 36-Mbp region of chromosome 11 derived from DBA/2 conferred an approximately threefold increase in mobilization (Fig. 1a) . To further narrow the interval conferring increased mobilization, we generated new subcongenic mice from line G by further backcrossing to C57BL/6 mice 10 ( Fig. 1b) . Mobilization was determined using a standard G-CSF mobilization protocol 10, 11 (Fig. 1c) . Subcongenic lines 106, 1023 and 1804 showed increased mobilization compared to C57BL/6 mice, whereas line 338 had a phenotype similar to that of C57BL/6 (Fig. 1c) . These data narrow the interval conferring enhanced mobilization to the 14.7-19.5 Mbp region of chromosome 11 (Fig. 1b) .
Twelve genes are located within this 5-Mbp interval of chromosome 11 (Supplementary Table 1 ). Gene chip expression analyses of 11 of these transcripts (as represented on the Affymetrix MOE430 microarray) revealed differential expression of the genes Egfr and C1d between line G and C57BL/6 mice (Fig. 1d) . Because EGFR is known to have a key role in both cell adhesion and migration, we selected it as a potential quantitative trait gene in the interval. By quantitative real-time RT-PCR, we confirmed that Egfr expression was decreased in hematopoietic progenitor cells (HPCs) isolated from the bone marrow of line G and line 1804 compared to HPCs of C57BL/6 mice under steady state conditions and, more markedly, upon G-CSF-induced mobilization (Fig. 1e) . We also found that Egfr expression was lower in HPCs compared to other tissues of C57BL/6 mice (Supplementary Table 2 ). These data demonstrate an inverse correlation between Egfr expression with mobilization and imply a negative role for EGFR signaling in mobilization.
To test for a possible inhibitory role of EGFR signaling in mobilization, we treated C57BL/6 mice with a combination of G-CSF and epidermal growth factor (EGF). We found a dose-dependent inhibition of HPC mobilization by EGF (Fig. 2a) . EGF in the dose range tested did not restrict steady-state mobilization in mice not treated with G-CSF (data not shown). To test whether activation of EGFR signaling with EGF reduced stem cell mobilization, we performed competitive transplants with equal volumes of blood from C57BL/6 l e t t e r s 1 1 4 2 VOLUME 16 | NUMBER 10 | OCTOBER 2010 nature medicine mice treated with G-CSF or with G-CSF and EGF (0.8 μg EGF per g body weight) (Fig. 2b) . Transplantation of peripheral blood from mice treated with G-CSF and EGF resulted in approximately fivefold less chimerism 3 months after transplant compared to peripheral blood from mice treated with G-CSF alone, corresponding to a decrease in repopulating units (RU) 12 from 1.9 ± 0.7 RU for G-CSF to 0.14 ± 0.07 for G-CSF plus EGF (Fig. 2c) . As suggested by the reduced EGFR expression in HPCs from line 1804 mice (Fig. 1e) , these mice were significantly less sensitive to inhibition of mobilization by EGF relative to C57BL/6 mice ( Fig. 2d) . EGFR is activated by several ligands in addition to EGF, including transforming growth factor-α (TGF-α), betacellulin and heparin-binding EGF (HB-EGF) 12 . Expression of TGF-α and HB-EGF mRNAs, but not of EGF or betacellulin mRNAs, was detected by RT-PCR in bone marrow cells (Fig. 2e) . Expression array analyses previously revealed expression of EGF in bone marrow stromal cells 13 . Thus, multiple EGFR ligands are found in bone marrow. The overall goal of these studies was to identify therapeutic targets to increase stem cell mobilization. To test the hypothesis that inhibition of EGFR signaling would enhance mobilization, we used both genetic and pharmacological approaches. As a genetic model we used mice that are heterozygous for the waved-2 mutation in Egfr (wa2/+ mice) a strain that has a spontaneous mutation in the tyrosine kinase domain of EGFR, substantially reducing receptor activity 14 . To determine the consequences of reduced EGFR signaling in hematopoietic cells on mobilization, we reconstituted B6.SJL(BoyJ) Ly5.1 recipient mice with either littermate control or wa2/+ bone marrow (Fig. 3a) . Mice reconstituted with wa2/+ bone marrow showed a significant increase in mobilization compared to controls (Fig. 3b) . Steady-state levels of colony-forming cells (CFCs) in bone marrow were similar in C57BL/6, line G and wa2/+ mice, indicating that the increase mobilization in line G or wa2/+ HPCs is related to the number of HPCs in BM prior to mobilization (data not shown).
To determine whether the Egfr mutation affects mobilization by acting in bone marrow cells or HPCs, as predicted from our previously published experiments analyzing mobilization in congenic line G 10 , or alternatively in bone marrow stromal cells, we performed competitive transplants and mobilizations with bone marrow cells from wa2/+ or wild-type (WT) mice (Ly5.2) admixed with competitor bone marrow cells (Ly5.1) (Fig. 3c) . Donor chimerism was 50% in both cases (Fig. 3d) , but a significantly higher frequency of Ly5.2 CFCs were mobilized in mice reconstituted with wa2/+ bone marrow (80%) compared to mice reconstituted with WT bone marrow (60%) (Fig. 3e) , with a 2.6-fold increase in wa2/+ CFCs in peripheral blood upon mobilization relative to control CFCs (calculations according to ref. 12). We also saw a similar skewing toward wa2/+ CFCs in spleen and bone marrow after mobilization (Supplementary Fig. 1a-c) as well as in the Lin − c-Kit + HPC compartment in peripheral blood (Supplementary Fig. 1d ). Mobilization of neutrophils, which are thought to supply the secondary signals leading to HSPC mobilization upon G-CSF treatment 15 , was not altered in wa2/+ competitive mobilization experiments (Supplementary Fig. 1e,f) suggesting that EGFR signals through a neutrophil-independent pathway in G-CSF-induced mobilization. Although these data support a primarily HPC-intrinsic role of inhibition of EGFR signaling in enhancing mobilization, these data do not exclude the possibility that additional cell-extrinsic or systemic effects of reduced EGFR signaling influence HSPC mobilization efficiency.
To determine whether pharmacological inhibition of EGFR activity results in enhanced mobilization, C57BL/6 mice were mobilized with G-CSF and treated with erlotinib, a specific inhibitor of EGFR activity 16 . Treatment with erlotinib (2.5-10 μg per g body weight) during the G-CSF regimen increased mobilization of HPCs (Fig. 3f) . This treatment also increased mobilization of hematopoietic stem cells, as assessed by competitive transplantation of cells mobilized to peripheral blood, with an RU value of 1.1 ± 0.4 for G-CSF compared to RU values of 4.4 ± 1.2 and 7.6 ± 2.5 for erlotinib (5 μg and 10 μg per g body weight, respectively) (Fig. 3g,h and Supplementary  Fig. 2 ). Erlotinib did not promote mobilization in the absence of G-CSF (Supplementary Fig. 3) , implying that the action of erlotinib on mobilization depends on additional unidentified factors induced by G-CSF. Notably, whereas inhibition of G-CSF-induced mobilization by EGF or activation of mobilization by erlotinib resulted in an approximately twofold change in mobilization of HPCs (Figs. 2a and 3f) , l e t t e r s up to a fivefold change in repopulating units occurred in response to these pharmacological treatments (Figs. 2c and 3h) , implying a larger effect of EGFR signaling on the mobilization of stem than on progenitor cells. One explanation for this difference might be that changes in EGFR signaling alter the homing or engraftment ability of HSCs or both when transplanted into the recipient animal. Another explanation might be that HSCs are more sensitive to changes in EGFR signaling compared to HPCs. To identify possible mechanisms by which EGFR signaling alters mobilization, we examined known downstream targets of EGFR signaling, which include the family of small Rho GTPases (Rac1, Rac2 and Cdc42; refs. [17] [18] [19] . Changes in the activity of these proteins have previously been shown to play a key part in the migration and adhesion of HSPCs 6, 20, 21 . We performed effector domain pull-down experiments to determine whether activation of EGFR signaling affects the activity of the Rho GTPases (Fig. 4) . Mobilization by G-CSF resulted in increased activity of Cdc42 in C57BL/6 mice (Fig. 4j) . Consistent with activation of Cdc42 in fibroblasts in response to EGF 19 , activation of EGFR signaling by EGF in G-CSF-treated mice further increased Cdc42 activity in low-density bone marrow (LDBM) cells compared to G-CSF treatment alone (Fig. 4a) . Conversely, inhibition of EGFR signaling by erlotinib decreased the abundance of active Cdc42 compared to mice treated with G-CSF alone (Fig. 4b,c) . Additionally, phosphorylation of p38, a known downstream target of both Cdc42 and EGFR signaling 22, 23 , was substantially increased upon activation of EGFR by EGF (Supplementary Fig. 4) . Neither EGF nor erlotinib altered the cellular composition of LDBM (data not shown), excluding altered cellular composition as a cause for altered Cdc42 activity. We did not detect significant changes in the abundance of the GTPbound forms of Rac1 or Rac2 (data not shown). Collectively, these data demonstrate that changes in EGFR signaling upon G-CSF-induced mobilization affect the amount of active Cdc42 and additional downstream signaling events.
As release of cells from the stroma is a prerequisite for mobilization 24 and Cdc42 is known to be involved in HSPC adhesion, we tested the ability of bone marrow-derived HPCs from G-CSF-treated C57BL/6 mice to adhere to stroma in response to EGF or erlotinib treatment, as assessed with a cobblestone area-forming cell (CAFC) adhesion assay 11 . EGF treatment enhanced adhesion of HPCs from G-CSF-treated mice to stroma (Fig. 4d) , whereas treatment with erlotinib reduced adhesion (Fig. 4e) . Thus, EGFR signaling may alter HSPC mobilization by altering cell adhesion or chemoattraction. Adhesion and chemoattraction of HSPCs is mediated by integrins and chemokine receptors. We measured the expression of integrins α 4 and α 5 , the CXCR4 chemokine receptor 25 and CD26 (ref. 26 ) on Lin − c-Kit + HPCs isolated from G-CSF-treated mice also treated with or without EGF. The effect of EGF treatment on the expression of these proteins was either not significant or, in the case of CD26, less than 10% compared to G-CSF only, and these effects did not correlate with mobilization efficiency (Supplementary Fig. 5a-d) . These data suggest that additional receptors may be involved in altering cell adhesion upon activation of EGFR signaling, although we cannot exclude the possibility that changes in integrin activation status (which is crucial for the regulation of adhesion [27] [28] [29] [30] [31] ), rather than changes in integrin abundance at the cell surface, might be involved in EGF-mediated regulation of mobilization efficiency. We also found that activation of EGFR by EGF correlated with a reduction in the percentage of HPCs in the S phase of mitosis (Supplementary Fig. 5e ), suggesting that changes in cell cycle parameters may also contribute to inhibition of mobilization by EGF 30, 31 .
We next studied the role of the EGF-EGFR-Cdc42 axis on mobilization using two complementary genetic approaches. First, G-CSF-induced mobilization in WT mice was significantly reduced by treatment with EGF ( Fig. 4f) , whereas mobilization in naive, untransplanted wa2/+ mice was not affected (Fig. 4g) , implying that inhibition of mobilization by EGF depends on EGFR activity. In contrast to the experiments in which mice reconstituted with wa2/+ bone marrow showed a higher mobilization efficiency compared to mice reconstituted with bone marrow from littermate controls (Fig. 3a,b) , the number of HPCs mobilized in naive wa2/+ mice after G-CSF treatment was reduced in both peripheral blood and spleen compared to littermate controls, whereas the number of bone marrow CFCs was unchanged ( Fig. 4g and Supplementary Fig. 6a,b) . One possible explanation for these discrepant results with respect to the role of EGFR signaling in mobilization is that constitutively reduced EGFR signaling in bone marrow stromal cells, in contrast to its role in HSPCs, confers reduced mobilization efficiency. To test this hypothesis, we transplanted B6.SJL(BoyJ) Ly5.1 bone marrow cells into wa2/+ or littermate mice and induced mobilization with G-CSF after hematopoietic reconstitution (2 months after transplantation). The number of mobilized HPCs in reconstituted wa2/+ mice was lower than that in reconstituted WT mice ( Supplementary  Fig. 6c,d) , indicating that constitutively low EGFR signaling either bodywide or specifically in bone marrow stromal cells of the recipient mice, or in both, impairs mobilization and suggests an effect of constitutively low EGFR signaling on bone marrow stromal cells. The effect of constitutively decreased EGFR activity in bone marrow cells with respect to mobilization is thus distinct from the effect of pharmacological transient inhibition of EGFR signaling induced by erlotinib in both bone marrow stromal cells and HSPCs, which resulted in enhanced mobilization (Fig. 3f-h) . The distinct outcomes of EGFR signaling pathways in bone marrow stromal cells and HSPCs are further supported by the finding that EGFR expression in C57BL/6 CD45-Ter119 − bone marrow stromal cells, in contrast to HSPCs, was not altered by G-CSF (Fig. 1e and Supplementary Fig. 7a) ; that inhibition of G-CSF-induced mobilization by EGF did not result in an altered percentage of bone marrow stromal cells ( Supplementary Fig. 7b) ; and that the expression of CXCL12, integrins α 4 and α 5 , vascular cell adhesion molecule-1 (VCAM-1) and CD44 in stromal cells was not different in mice treated with G-CSF plus EGF compared to G-CSF alone ( Supplementary  Fig. 7b-f and data not shown) 1,25,32,33 .
To unequivocally determine whether Cdc42 is necessary for altering mobilization upon EGFR signaling, we induced mobilization in mice that were selectively deficient in Cdc42 in bone marrow cells including HSPCs. G-CSF-induced mobilization was significantly enhanced in mice reconstituted with Cdc42 −/− bone marrow cells compared to mice reconstituted with WT control bone marrow cells (Fig. 4h,i , P = 0.03), and, similarly to data obtained in wa2/+ mice, mobilization of Cdc42 −/− HPCs was not significantly inhibited by EGF, unlike WT control cells (Fig. 4h,i) . Consistent with these data, experiments employing a small molecule inhibitor of Cdc42 activity also suggested that erlotinib increases mobilization by reducing Cdc42 activity (W.L., L. Wang, X. Shang, M.A.R., F. Marchioni et al., unpublished data). These data indicate that EGF-EGFR signaling affects mobilization through modulation of Cdc42 activity.
Last, to investigate the role of Cdc42 in our genetic model of interstrain differences in mobilization, we determined the amount of active Cdc42 in G-CSF-treated C57BL/6 and line 1804 congenic mice. Cdc42 activity in LDBM cells was increased in G-CSF-treated C57BL/6 mice relative to untreated mice, whereas it was not altered in 1804 mice (Fig. 4j) , suggesting that one mechanism of enhancing G-CSF-induced mobilization is through reduction of the amount of active Cdc42.
Mobilization of HSPCs is a quantitative trait, and the mechanisms responsible for the variability in mobilization observed in patients are unclear 34, 35 . Using a forward genetic approach, our data demonstrate a role for EGFR signaling in regulating mobilization, in part by regulating Cdc42 activity. The expression of the human EGFR protein is determined primarily by the abundance of its mRNA, which correlates with allelic polymorphisms 36 . Owing to an absence of definitive data on DNA polymorphisms and their functional relevance for the EGFR region in the mouse, both changes in EGFR expression as well as differences in EGFR activity might be responsible for the effects on mobilization in our genetic model system. Our data do not exclude that additional genes in the interval on chromosome 11, such as C1d, might further regulate mobilization by as yet unknown mechanisms.
Our data support a model in which relative changes in Cdc42 activity in response to EGF or erlotinib, with respect to the elevated baseline level set by G-CSF, are responsible for alterations in mobilization. Although our data point to effects on mobilization via the EGFR-Cdc42 pathway, the activation status of Cdc42 itself is not an indicator for general mobilization efficiency and has to be interpreted within the cellular and molecular context. This view is also supported by the overall context-dependent role of Cdc42 activity in hematopoiesis, as, in addition to our data, previous studies have shown that both the absence of Cdc42 activity in the knockout mouse model as well as elevated Cdc42 activity in aged mice correlate with elevated numbers of HSPCs in peripheral blood 11, 21, 37, 38 . Our data demonstrate that pharmacological inhibition of EGFR signaling enhances stem cell mobilization, suggesting that therapeutic application of EGFR inhibition might improve G-CSF-induced HSPC mobilization and stem cell therapy outcomes.
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